1159010-94-2 Usage
General Description
6-Hydroxy-5-Methylpyrimidine-4-carboxylic acid is a chemical compound that belongs to the class of organic compounds known as pyrimidinecarboxylic acids and derivatives. These are compounds containing a pyrimidine ring, which is a six-membered aromatic heterocycle that consists of two nitrogen atoms and four carbon atoms, bearing a carboxylic acid group. The specific structure of 6-Hydroxy-5-Methylpyrimidine-4-carboxylic acid, as the name implies, features a hydroxy group at the 6 position, a methyl group at the 5 position, and a carboxylic acid group at the 4 position. While data regarding its properties or uses may be limited, based on its structural characteristics, it could potentially be utilized in pharmaceuticals or as a building block in chemical synthesis.
Check Digit Verification of cas no
The CAS Registry Mumber 1159010-94-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,5,9,0,1 and 0 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1159010-94:
(9*1)+(8*1)+(7*5)+(6*9)+(5*0)+(4*1)+(3*0)+(2*9)+(1*4)=132
132 % 10 = 2
So 1159010-94-2 is a valid CAS Registry Number.
1159010-94-2Relevant articles and documents
NEW SELECTIVE CCR2 ANTAGONISTS
-
Paragraph 0387;0388, (2013/06/27)
The present invention relates to novel and selective antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD as well as pain.
NEW SELECTIVE CCR2 ANTAGONISTS
-
Page/Page column 86-87, (2013/02/28)
The present invention relates to novel and selective antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD as well as pain.
NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF
-
Page/Page column 87, (2011/07/07)
The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) of Formula (I) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
